NICE recommends avatrombopag to treat thrombocytopenia in chronic liver disease
March 4, 2020Research and Development Avatrombopag, NHS, NICE, UK, chronic liver disease
UK drug watchdog NICE has announced its final draft guidance recommending avatrombopag for routine use on the NHS in England …
Trump meets pharmaceutical executives to discuss COVID-19 vaccine
March 4, 2020Research and Development COVID-19, Chinese Coronavirus, Trump, Wuhan Coronavirus, coronavirus
President Trump has met with several representatives of the top pharmaceutical companies to discuss progress being made on a coronavirus …
MSD’s Phase 3 study of lymphoma treatment meets primary endpoints
March 3, 2020Manufacturing and Production B-cell lymphoma, classical Hodgkin Lymphoma, lymphoma
MSD announced that its Phase 3 study of Keytruda (pembrolizumab) for the treatment of adults with relapsed or refractory classical …
Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal
March 3, 2020Manufacturing and Production, Sales and Marketing Cancer, Forty Seven, Gilead, acquisition, oncology, pharma
Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …
Novartis’ subsidiary Sandoz agrees to pay $195 million to settle antitrust case
March 3, 2020Manufacturing and Production Novartis, US Courts, generic drugs, generics, price fixing, price-fixing
Novartis’ Sandoz will pay a $195 million criminal penalty to resolve charges that it conspired to price-fix, rig bids and …
Sanofi scores FDA approval for Sarclisa combo in relapsed, refractory multiple myeloma
March 3, 2020Manufacturing and Production, Sales and Marketing Cancer, Sanofi, Sarclisa, multiple myeloma, pharma
Sanofi’s monoclonal antibody and CD-38 inhibitor Sarclisa (isatuximab-irfc) has been awarded marketing authorisation from the FDA in the treatment of …
99% of Doctors feel NHS is not ready to deal with coronavirus, new survey finds
March 3, 2020Manufacturing and Production Boris, Chinese Coronavirus, UK Coronavirus, Wuhan Coronavirus, coronavirus
Most NHS doctors, that partcipated in a survey, feel the organization is not well prepared to deal with a major …
Funding overview for the pharmaceutical industry and outlook for 2020
March 2, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2020, M&A, MA, feature, mergers & acquisitions, opinion, pharma
This article was originally published in the January/February 2020 issue of Pharmafocus.With the advent of a New Year, Michael Jewell, …
GW Pharma takes back control of UK Sativex sales from Bayer
March 2, 2020Sales and Marketing Bayer, GW Pharma, Sativex, UK
British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis …
UK Health Secretary says no tactics will be “off the table” in dealing with coronavirus
March 2, 2020Sales and Marketing Chinese Coronavirus, MERS, Sars, Wuhan Coronavirus, coronavirus
British Health Secretary Matt Hancock has said nothing will be “off the table” in tackling the coronavirus as cases in …
FDA approves first generic version of Shkreli-hiked toxoplasmosis drug Daraprim
March 2, 2020Sales and Marketing Cerovene, Daraprim, FDA, Martin Shkreli, generics, pharma
The FDA has awarded approval to the first generic medicine for the treatment of toxoplasmosis, authorising Cerovene’s version of Daraprim …
Sanofi set to pay $11.9 million to resolve kickback probe, US Justice Department announces
March 2, 2020Sales and Marketing Co pays, Justice department, Medicaid, Medicare, Sanofi, insurance
The Justice Department have announced that Sanofi SA have agreed to pay $11.85 million to resolve allegations it used a …
Experimental drug could treat dyskinesia in people with Parkinson’s
March 2, 2020Sales and Marketing Parkinson's, Parkinson's disease, dyskinesia, spasms
Results from a new study researching treatment for dyskinesia has offered hope that it may be treatable in people with …
Takeda’s subcutaneous vedolizumab nabs CHMP nod for maintenance of ulcerative colitis and Crohn’s
February 28, 2020Medical Communications, Sales and Marketing CHMP, EMA, Takeda, vedolizumab
Takeda’s subcutaneous formulation of its gut-selective biologic vedolizumab has secured recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal …
Top Ten most popular articles on Pharmafile.com this week
February 28, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chinese Coronavirus, Johnson and Johnson, Wuhan Coronavirus, coronavirus
The coronavirus continues to spread across the globe as the US launch their first trials for Gilead’s ebola drug remdesivir …
Acacia Pharma secures first FDA approval with Barhemsys for postoperative nausea and vomiting
February 28, 2020Medical Communications, Sales and Marketing Acacia, FDA, UK, US, pharma
UK-based Acacia Pharma has secured its first US approval with the FDA’s decision to authorise Barhemsys (amisulpride injection) for the …
First coronavirus case confirmed in Wales as number of infected in Britain rises to 19
February 28, 2020Medical Communications British Coronavirus, Chinese Coronavirus, Wales coronavirus, Wuhan Coronavirus, coronavirus
A person has been diagnosed with coronavirus in Wales, with the number of infected continuing to rise as numerous sporting …
E. coli strain in the gut may increase risk of bowel cancer, new study finds
February 28, 2020Medical Communications Cancer, E. coli, bowel cancer, bowels, cancer research, e coli, oncology
A type of E. coli infection may increase a person’s chance of developing bowel cancer, according to a new study …
The March 2020 issue of Pharmafocus is available to read free online now!
February 27, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing England, Pharmafocus, UK, mumps, pharma, pharmacovigilance, type 2 diabetes
The latest monthly edition of Pharmafocus, the March issue, is available to read for free online now! The coronavirus continues …
FDA advisory committee narrowly backs Eli Lilly’s Cyramza combo for metastatic EGFR+ NSCLC
February 27, 2020Sales and Marketing Eli Lilly, FDA, cyramza, pharms
Eli Lilly’s Cyramza (ramucirumab) has edged closer to US approval after it scored a recommendation from the FDA’s Oncologic Drugs …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
